Financials Results for the quarter ended June 30, 2026

Date: July 21, 2026 BSE Limited, National Stock Exchange of India Limited 20th Floor, P.J. Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai - 400001. Mumbai – 400 051 BSE Scrip Code: 544449 NSE Scrip Symbol: ANTHEM Subject: Outcome of the Board Meeting held on Tuesday, July 21, 2026 Dear Sir/Ma’am Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR”), we would like to inform you that the Board of Directors of Anthem Biosciences Limited (formerly known as Anthem Biosciences Private Limited) ("Company") at their meeting held on Tuesday, July 21, 2026 which commenced at 01:45 p.m. and concluded at 03:35 p.m. have inter-alia, approved the Unaudited Standalone and Consolidated Financial Results along with Limited Review Report of Statutory Auditors for the quarter ended June 30, 2026. The said financials results were duly reviewed and recommended by Audit Committee at its meeting held on same day to the Board. A copy of the said Unaudited Standalone and Consolidated Financial Results along with Limited Review Report of the Statutory Auditors are enclosed herewith and the extract of the results will be published in the newspapers as required under Regulation 47(1) of SEBI LODR Regulations. The above intimation is also available on the Company’s website at https://anthembio.com/. We request you to kindly take the same on record. Thanking you, Yours truly, For Anthem Biosciences Limited (Formerly known as Anthem Biosciences Private Limited) Divya Prasad Company Secretary & Compliance Officer Membership No: A41438 K. P. RAO & CO. 'Poornima', llnd Floor,25, State Bank Road, CHARTERED ACCOUNTANTS Bangalore 560 001. Karnataka, lndia. K. P, RAO K, VISWANATH 080 - 25587385 i 2558681,1 H.N. ANIL S, PRASHANTH Fax 080 - 25594661 MOHAN R LAVI P RAVINORANATH E-mail info@kprao.co.in Independent Auditor's Review Report on the quarterly Unaudited Standalone Financial results of Anthem Biosciences Limited pursuant to the Regulations 3-1 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) Review report to The Board of Directors of Anthem Biosciences Limited Bangalore We have reviewed the Unaudited Standalone Financial result of Anthem Biosciences Limited (the "Company"). for the quarter ended June 30. 2026 included in the accompanying "Statement of Unaudited Standalone Financial results for the quarter ended June 30,2026" (the Statement) attached herewith. being submitted by the Company pursuant to the requirements of Regulation J3 ol the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (Listing Regulations). 2. This statement, which is the responsibility of the Company's management and approved by the company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "lnterim Financial Reporting" ("lnd AS 34"). prescribed under Section 133 of the Companies Act, 201 3 read with relevant rules issued thereunder and other accounting principles generally accepted in India and SEBI (Listing Obligations and Disclosure Requirements) Regulations. 2015. as amended. Our responsibility is to express a conclusion on the Statement based on our review. 3. we conducted our review of the Statement in accordance with the Standard on Review Engagements ("sRE') 2410 'Review of Interim Financial Information performed by the Independent Auditor ofthe Entity', issued by the Institute ofChartered Accountants of India c'lcAl'). A review of interim financial information consists of making inquiries' primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143( l0) ofthe companies Act, 201 3 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not ex oprnron Branches Hyderabad : 3rd Floor, Dl, 6-3-652, Kautilya. Somajiguda, Hyderabad _ 5OO 082. ph.: 040-23322310 _. Mysore : 14, 2nd Main, First Stage, Vijayanagar, Mysore - 570017. ph.:0g21_4271908 Chehnai Flat2-A,second Froor, shruthi 3r. 8th cross sireet,'5hasrri".9"r,iJ"yrr, ir"nnai -600020. ph.: o".- 24903137 /45s11564 K. P. RAO & CO. Continuation Sheet CHARTERED ACCOUNTANTS 4. Based on our review conducted as stated in paragraph 3 above. nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in Indiq has not disclosed the information required to be disclosed in terms olRegulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 20 I 5, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement. For K. P. Rao & Co., C] d Accountants 3135S 4 881{GATURU Mohan R Lavi Partner Membership No. 029340 Place: Bangalore Date: July 21,2026 UDIN: 26029340ETJRWW,1382 ANTHEM BIOSCIENCES LIMITED CORPORATE IDENTITY NUMBER: L24233KA2006PLC039703 REGISTERED AND CORPORATE OFFICE: NO 49, F1&F2, CANARA BANK ROAD, BOMMASANDRA INDUSTRIAL AREA, PHASE-I, BOMMASANDRA, BANGALORE-560099. KARNATAKA INDIA. Email : investors.abl@anthembio.com Telephone: +91 080 6672 4000 Website: www.anthembio.com STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026 Rs in Mn Quarter ended Year End Particulars 30/06/2026 31/03/2026 30/06/2025 31/03/2026 Unaudited Unaudited Unaudited Audited Income: Revenue from operations 3,838.42 5,825.01 5,380.11 20,893.12 Other income 286.00 606.25 2 77.28 1,820.75 Total Income 4,124.42 6,431.26 5,657.39 22,713.87 Expenses: Cost of materials consumed 1,449.45 1,500.74 1,623.95 6,967.51 Changes in inventories of finished goods, work-in-progress and stock in trade ( 23.64) 502.54 6 86.72 986.91 Employee benefit expenses 727.79 667.25 6 85.69 2,639.24 Finance cost 7.63 15.83 1 6.06 65.47 Depreciation and amortisation expense 223.10 262.84 2 26.12 995.65 Other expenses 376.49 484.57 4 29.46 1,788.25 Total Expenses 2,760.82 3,433.76 3,668.01 13,443.04 Profit before exceptional items and tax 1,363.60 2,997.50 1,989.38 9,270.84 Exceptional items - (9.71) - 240.13 Profit before tax 1,363.60 3,007.21 1,989.38 9,030.70 Tax expense Current tax 347.05 897.06 5 00.69 2,413.05 Deferred tax ( 3.55) ( 6.50) 5 .29 ( 87.99) Total tax expenses 343.50 890.56 5 05.98 2,325.06 Profit for the Period/Year 1,020.09 2,116.65 1,483.40 6,705.64 Other comprehensive income Other comprehensiveincome/(loss) not to bereclassified to profit or loss in subsequent period 9.37 (10.93) 20.08 (20.04) Income tax on above (2.36) 2.75 (5.05) 5.04 Othercomprehensiveincome/(loss)tobereclassifiedtoprofitorlossinsubsequent period 2.83 - - - Income tax on above (0.71) - - - Other comprehensive income/(loss) for the period/year 9.13 (8.18) 15.03 (15.00) Total comprehensive income for the period/year 1,029.22 2,108.47 1,498.43 6,690.64 Paid-up equity share capital (face value of Rs.2 each) 1,126.77 1,123.43 1,123.22 1,123.43 Reserves excluding revaluation reserves as per balance sheet i.e. 'Other Equity' 30,723.58 Earnings per share Not annualised Not annualised Not annualised Annualised Basic 1.81 3.77 2 .65 11.95 Diluted 1.80 3.73 2 .64 11.82 See accompaning notes to financial results Notes to standalone financial results These unaudited standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed 1 underSection133oftheCompaniesAct,2013,asamended,readwi [Showing first 8,000 characters — download PDF for full document]